Regeneron, Sanofi arthritis drug trial data shows it may only help 'critical' COVID-19 patients

(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday that their arthritis drug Kevzara may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease.The drugmakers said they would test high doses of Kevzara only in "critically ill" COVID-19 patients based on guidance from an independent committee that reviewed early trial data, which showed the drug was not beneficial for "severe"..